K
Karen M. Jones
Researcher at United States Department of Veterans Affairs
Publications - 25
Citations - 3519
Karen M. Jones is an academic researcher from United States Department of Veterans Affairs. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 16, co-authored 20 publications receiving 3144 citations. Previous affiliations of Karen M. Jones include University of Texas Southwestern Medical Center & New York University.
Papers
More filters
Journal ArticleDOI
Radical prostatectomy versus observation for localized prostate cancer.
Timothy J Wilt,Michael K. Brawer,Karen M. Jones,Michael J. Barry,William J. Aronson,Steven Fox,Jeffrey R. Gingrich,John T. Wei,Patricia Gilhooly,B. Mayer Grob,Imad Nsouli,Padmini Iyer,Ruben Cartagena,Glenn Snider,Claus G. Roehrborn,Roohollah Sharifi,William Blank,Parikshit Pandya,Gerald L. Andriole,Daniel J. Culkin,Thomas M. Wheeler +20 more
TL;DR: Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer mortality, as compared with observation, through at least 12 years of follow-up.
Journal ArticleDOI
Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?
Michael J. Barry,William O. Williford,Yuchiao Chang,Madeline Machi,Karen M. Jones,Elizabeth Walker-Corkery,Herbert Lepor +6 more
TL;DR: These data provide guidance for investigators using the AUA symptom index and BPH impact index as outcome measures and the baseline scores strongly influenced this relationship.
Journal ArticleDOI
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Timothy J Wilt,Karen M. Jones,Michael J. Barry,Gerald L. Andriole,Daniel J. Culkin,Thomas M. Wheeler,William J. Aronson,Michael K. Brawer +7 more
TL;DR: After nearly 20 years of follow‐up among men with localized prostate cancer, surgery was not associated with significantly lower all‐cause or prostate‐cancer mortality than observation and treatment was primarily for asymptomatic, local, or biochemical (prostate‐specific antigen) progression.
Journal ArticleDOI
Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD: A Randomized Trial
John H. Krystal,Robert A. Rosenheck,Joyce A. Cramer,Jennifer C. Vessicchio,Karen M. Jones,Julia E. Vertrees,Rebecca A. Horney,Grant D. Huang,Christopher Stock +8 more
TL;DR: In this article, the second-generation antipsychotic risperidone was used as an adjunct to ongoing pharmacologic and psychosocial treatments for veterans with chronic military-related PTSD.
Journal ArticleDOI
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer
Timothy J Wilt,Michael K. Brawer,Michael J. Barry,Karen M. Jones,Young Kwon,Jeffrey R. Gingrich,William J. Aronson,Imad Nsouli,Padmini Iyer,Ruben Cartagena,Glenn Snider,Claus G. Roehrborn,Steven Fox +12 more
TL;DR: Comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy versus watchful waiting conducted in Scandinavia indicated that PIVOT enrollees are representative of men being diagnosed and treated in the U.S. and quite different from men in the Scandinavian trial.